Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

מאת Offner, Fritz, Samoilova, Olga, Osmanov, Evgenii, Eom, Hyeon-Seok, Topp, Max S., Raposo, João, Pavlov, Viacheslav, Ricci, Deborah, Chaturvedi, Shalini, Zhu, Eugene, van de Velde, Helgi, Enny, Christopher, Rizo, Aleksandra, Ferhanoglu, Burhan
הוצא לאור ב Blood (2015)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase...

מאת Zinzani, Pier Luigi, Khuageva, Nuriet K, Wang, Huaqing, Garicochea, Bernardo, Walewski, Jan, Van Hoof, Achiel, Soubeyran, Pierre, Caballero, Dolores, Buckstein, Rena, Esseltine, Dixie-Lee, Theocharous, Panteli, Enny, Christopher, Zhu, Eugene, Elsayed, Yusri A, Coiffier, Bertrand
יצא לאור 2012

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

מאת Reece, Donna E., Hegenbart, Ute, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Bladé, Joan, Fermand, Jean-Paul, Hassoun, Hani, Heffner, Leonard, Kukreti, Vishal, Vescio, Robert A., Pei, Lixia, Enny, Christopher, Esseltine, Dixie-Lee, van de Velde, Helgi, Cakana, Andrew, Comenzo, Raymond L.
יצא לאור 2014

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

מאת Ludwig, Heinz, Greil, Richard, Masszi, Tamas, Spicka, Ivan, Shpilberg, Ofer, Hajek, Roman, Dmoszynska, Anna, Paiva, Bruno, Vidriales, María‐Belén, Esteves, Graca, Stoppa, Anne Marie, Robinson, Don, Chaturvedi, Shalini, Ataman, Ozlem, Enny, Christopher, Feng, Huaibao, van de Velde, Helgi, Viterbo, Luisa
הוצא לאור ב Br J Haematol (2015)